FDA Releases New Guidance on Real-World Drug Safety Studies
Published Date: 3/4/2026
Notice
Summary
The FDA just released new rules to help drug makers and researchers use real-world data to check medicine safety better and faster. This update affects anyone doing non-interventional studies on drugs, vaccines, or biologics, replacing older guidance and aiming to make safety checks smoother without extra costs. The new guidance is effective now and encourages clear planning, smart data use, and honest reporting to keep medicines safe for everyone.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Final M14 Guidance Available
The FDA issued the final ICH M14 guidance on March 4, 2026 for non-interventional studies that use real-world data to assess the safety of medicines (drugs, vaccines, and biological products). The guidance lays out recommended principles for planning, designing, analyzing, reporting, and submitting these studies.
Enhanced Methodology and Reporting Guidance
The final guidance includes comprehensive recommendations and enhanced discussion on Initial Design and Feasibility, the Conceptual Framework, quantitative bias analysis, and protocol development including characteristics and types of data sources. These revisions followed public comment and were incorporated before endorsement in September 2025.
Older Guidance Withdrawn and Draft Finalized
The final M14 guidance finalizes the July 5, 2024 draft and, upon publication, FDA intends to withdraw the prior guidance titled "Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data" published May 14, 2013. The final guideline was endorsed by ICH regulatory agencies in September 2025.
No New Paperwork Burden
The guidance contains no new collection of information under the Paperwork Reduction Act, and it references previously approved FDA information collections (for example, OMB control numbers 0910-0014, 0910-0001, and others).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2026-04252, E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports; International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released new rules for drug companies on how to track and report safety info after a drug is approved. This update includes fresh ways to use data from places like social media and patient programs to keep medicines safe. Drug makers should get ready to follow these clearer, modern rules starting now, helping protect patients without extra costs.
Next: 2026-04255, Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V SAPPHIRE
The Maritime Administration is checking if the foreign-built small passenger vessel M/V SAPPHIRE can be used for U.S. coastwise trade without hurting American shipbuilders or businesses. They want your thoughts by April 3, 2026, before making a decision. This affects companies using small passenger vessels and could impact the market for U.S.-built boats.